These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1536 related items for PubMed ID: 19154448

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.
    Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G.
    J Urol; 2007 Apr; 177(4):1283-6; discussion 1286. PubMed ID: 17382713
    [Abstract] [Full Text] [Related]

  • 23. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.
    Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, Catton CN, McLean M, Moore M, Tannock IF, Gospodarowicz MK.
    Urol Oncol; 2007 Apr; 25(4):303-9. PubMed ID: 17628296
    [Abstract] [Full Text] [Related]

  • 24. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL, Shipley WU, Kaufman DS, Zehr EM, Heney NM, Althausen AF, McGovern FJ.
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [Abstract] [Full Text] [Related]

  • 25. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.
    Boorjian SA, Zhu F, Herr HW.
    BJU Int; 2010 Aug; 106(3):357-61. PubMed ID: 20002665
    [Abstract] [Full Text] [Related]

  • 26. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM, Khalil S, Salem EA, ElAdl M, Nawar N, Zaiton F.
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [Abstract] [Full Text] [Related]

  • 27. Combined modality treatment with bladder preservation for muscle invasive bladder cancer.
    Sabaa MA, El-Gamal OM, Abo-Elenen M, Khanam A.
    Urol Oncol; 2010 May; 28(1):14-20. PubMed ID: 18818110
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Organ preservation for muscle-invasive bladder cancer by transurethral resection.
    Leibovici D, Kassouf W, Pisters LL, Pettaway CA, Wu X, Dinney CP, Grossman HB.
    Urology; 2007 Sep; 70(3):473-6. PubMed ID: 17905099
    [Abstract] [Full Text] [Related]

  • 31. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?
    Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE.
    J Urol; 2004 Jul; 172(1):70-5. PubMed ID: 15201740
    [Abstract] [Full Text] [Related]

  • 32. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 33. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up.
    Given RW, Parsons JT, McCarley D, Wajsman Z.
    Urology; 1995 Oct; 46(4):499-504; discussion 504-5. PubMed ID: 7571218
    [Abstract] [Full Text] [Related]

  • 34. Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient.
    Kachnic LA, Shipley WU, Griffin PP, Zietman AL, Kaufman DS, Althausen AF, Heney NM.
    Cancer J Sci Am; 1996 Oct; 2(2):79-84. PubMed ID: 9166504
    [Abstract] [Full Text] [Related]

  • 35. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y, Oogo Y, Takase K, Hamano A, Yamashita Y, Noguchi S, Satomi Y.
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [Abstract] [Full Text] [Related]

  • 36. Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma.
    Granfors T, Tomic R, Ljungberg B.
    Scand J Urol Nephrol; 2009 Nov; 43(4):293-9. PubMed ID: 19363744
    [Abstract] [Full Text] [Related]

  • 37. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

  • 38. Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer.
    Rosenbaum RS, Park MC, Fleischmann J.
    Urology; 1996 Feb; 47(2):208-11. PubMed ID: 8607236
    [Abstract] [Full Text] [Related]

  • 39. [Radical cystectomy for superficial tumors in the BCG era].
    Huguet Pérez J, Palou J, Millán Rodríguez F, Villavicencio Mavrich H, Rodríguez JV.
    Arch Esp Urol; 2002 Feb; 55(1):50-6. PubMed ID: 11957752
    [Abstract] [Full Text] [Related]

  • 40. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM.
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 77.